Background: Endovenous interventional procedures can be used in addition to therapeutic anticoagulation to treat deep vein thrombosis in selected patients with proximal vein involvement (vena cava, iliac and/or common femoral). The aim of this study was to compare venous patency and the post-thrombotic syndrome (PTS) in patients treated with pharmaco-mechanical catheter-directed thrombolysis (PMT) versus recanalization-stenting for PTS after a proximal lower limb deep vein thrombosis. Methods: Between January 2014 and December 2020, this retrospective and monocentric study included patients with very symptomatic acute iliofemoral deep vein thrombosis treated with PMT within 21 days after diagnosis (PMT group) and patients with PTS caused by chronic venous obstruction treated with recanalization and stenting (CRS group). Results: A total of 116 patients were included (26 PMT, 90 CRS). The rate of primary patency was 81.8% (18/22 patients) in the PMT group and 78.4% (69/88) in the CRS group (P>0.99). The rate of venous patency at the last follow-up was 76.9% (20/26) in the PMT group and 82.2% (74/90) in the CRS group (P=0.57). The median number of stents was 2 (range, 0-5) in the PMT group and 3 (range, 0-7) in the CRS group (P<0.001). The median stent length was 150 mm (range, 60-390 mm) and 280 mm (range, 120-820 mm), respectively (P<0.001). The median last Villalta score was 2 (range, 0-10) in the PMT group and 2 (range, 0-21) in the CRS group (P=0.55). The rate of venous claudication at the last follow-up was 19.0% (4/21) in the PMT group and 12.0% (10/83) in the CRS group (P=0.47). Conclusions: In this study, there was no difference in venous patency and in the rate and severity of PTS between the PMT and CRS groups. The number of stent and their length were significantly lower in the PMT group compared with the CRS group. 2022 Quantitative Imaging in Medicine and Surgery. All rights reserved.
Background: Endovenous interventional procedures can be used in addition to therapeutic anticoagulation to treat deep vein thrombosis in selected patients with proximal vein involvement (vena cava, iliac and/or common femoral). The aim of this study was to compare venous patency and the post-thrombotic syndrome (PTS) in patients treated with pharmaco-mechanical catheter-directed thrombolysis (PMT) versus recanalization-stenting for PTS after a proximal lower limb deep vein thrombosis. Methods: Between January 2014 and December 2020, this retrospective and monocentric study included patients with very symptomatic acute iliofemoral deep vein thrombosis treated with PMT within 21 days after diagnosis (PMT group) and patients with PTS caused by chronic venous obstruction treated with recanalization and stenting (CRS group). Results: A total of 116 patients were included (26 PMT, 90 CRS). The rate of primary patency was 81.8% (18/22 patients) in the PMT group and 78.4% (69/88) in the CRS group (P>0.99). The rate of venous patency at the last follow-up was 76.9% (20/26) in the PMT group and 82.2% (74/90) in the CRS group (P=0.57). The median number of stents was 2 (range, 0-5) in the PMT group and 3 (range, 0-7) in the CRS group (P<0.001). The median stent length was 150 mm (range, 60-390 mm) and 280 mm (range, 120-820 mm), respectively (P<0.001). The median last Villalta score was 2 (range, 0-10) in the PMT group and 2 (range, 0-21) in the CRS group (P=0.55). The rate of venous claudication at the last follow-up was 19.0% (4/21) in the PMT group and 12.0% (10/83) in the CRS group (P=0.47). Conclusions: In this study, there was no difference in venous patency and in the rate and severity of PTS between the PMT and CRS groups. The number of stent and their length were significantly lower in the PMT group compared with the CRS group. 2022 Quantitative Imaging in Medicine and Surgery. All rights reserved.
Entities:
Keywords:
Deep vein thrombosis (DVT); Villalta score; pharmaco-mechanical catheter-directed thrombolysis (PMT); post-thrombotic syndrome (PTS); venous angioplasty and stenting
Authors: R Guanella; T Ducruet; M Johri; M-J Miron; A Roussin; S Desmarais; F Joyal; J Kassis; S Solymoss; J S Ginsberg; D L Lamping; I Shrier; S R Kahn Journal: J Thromb Haemost Date: 2011-12 Impact factor: 5.824
Authors: Rick T Ikesaka; Susan R Kahn; Jean-Philippe Galanaud; Fernando J Vazquez; Graham Roche-Nagle; Marc Carrier; Gregoire Le Gal; Marc Rodger; Esteban Gandara Journal: Thromb Res Date: 2017-09-15 Impact factor: 3.944
Authors: K Guillen; N Falvo; M Nakai; O Chevallier; S Aho-Glélé; C Galland; E Demaistre; L Pescatori; M Samson; S Audia; B Bonnotte; M Midulla; R Loffroy Journal: Diagn Interv Imaging Date: 2019-04-27 Impact factor: 4.026
Authors: Young Erben; Haraldur Bjarnason; Gudrun L Oladottir; Robert D McBane; Peter Gloviczki Journal: J Vasc Surg Venous Lymphat Disord Date: 2018-01-11
Authors: Suresh Vedantham; Samuel Z Goldhaber; Jim A Julian; Susan R Kahn; Michael R Jaff; David J Cohen; Elizabeth Magnuson; Mahmood K Razavi; Anthony J Comerota; Heather L Gornik; Timothy P Murphy; Lawrence Lewis; James R Duncan; Patricia Nieters; Mary C Derfler; Marc Filion; Chu-Shu Gu; Stephen Kee; Joseph Schneider; Nael Saad; Morey Blinder; Stephan Moll; David Sacks; Judith Lin; John Rundback; Mark Garcia; Rahul Razdan; Eric VanderWoude; Vasco Marques; Clive Kearon Journal: N Engl J Med Date: 2017-12-07 Impact factor: 176.079